Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares grows in line with its trailing trend
Q1 FY2026 weighted avg shares of 21.82M shares rose 0.6% year over year, in line with the +1.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.7% a year.
Context
- Weighted avg shares increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.6% toward the trailing-twelve-month pace of +1.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 21.82M USD
- Year-over-year change
- +0.6%
- 3-year CAGR
- +0.7%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.82M | +0.6% |
| FY2024 | 2024-12-31 | 21.7M | +1.5% |
| FY2023 | 2023-12-31 | 21.38M | +0.0% |
| FY2022 | 2022-12-31 | 21.38M | — |
Weighted Avg Shares vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's LTM Mar 2026 weighted avg shares of 21.77M shares is the 8th highest of the 11 companies compared; the peer median is 63.58M shares.
- Its year-over-year change of +1.1% is the 9th highest of 11, against a peer median of +16.4%.
- Over three fiscal years its annual growth of +0.7% compares with a peer median of +25.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 158.02M | +71.7% | +50.6% | |
| LTM Mar 2026 | 126.35M | +0.5% | +0.4% | |
ZURAZura Bio Limited | LTM Mar 2026 | 98.81M | +34.9% | +76.1% |
| LTM Mar 2026 | 94.18M | +3.6% | +15.4% | |
| LTM Mar 2026 | 64.63M | +7.9% | +14.8% | |
| LTM Mar 2026 | 62.52M | +2.9% | +23.4% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | 44.51M | +24.9% | +27.5% |
| LTM Mar 2026 | 21.77M | +1.1% | +0.7% | |
| LTM Mar 2026 | 21.37M | +0.6% | +1.2% | |
| LTM Mar 2026 | 15.86M | +130.2% | +599.3% | |
| LTM Mar 2026 | 10.86M | +66.5% | +40.6% | |
| Peer median (excluding AARD) | 63.58M | +16.4% | +25.5% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 7.17M | 4.48M | 17.36M | 48.94M |
| Selling, General & Admin | 2.7M | 2.17M | 5.31M | 13.79M |
| Operating Expenses | 11.36M | 7.42M | 22.79M | 62.73M |
| Depreciation & Amortization | 110K | 97K | 16K | 36K |
| EBITDA | (10.76M) | (6.56M) | (22.65M) | (57.56M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (11.36M) | (7.42M) | (22.79M) | (62.73M) |
| Operating Margin | — | — | — | — |
| Interest Income | 120K | 1.42M | 2.41M | 5.14M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.2M) | 207K | 2.2M | 5.13M |
| Income Before Tax | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.63) | (0.34) | (0.95) | (2.64) |
| EPS (Diluted) | (0.63) | (0.34) | (0.95) | (2.64) |
| Weighted Avg Shares | 21.38M | 21.38M | 21.7M | 21.82M |
| Weighted Avg Shares (Diluted) | 21.38M | 21.38M | 21.7M | 21.82M |
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.